BioCentury
ARTICLE | Company News

ADC Therapeutics, BZL Biologics deal

July 22, 2013 7:00 AM UTC

ADC received exclusive rights to an antibody against prostate-specific membrane antigen ( PSMA; FOLH1; GCPII) from BZL to treat prostate cancer. ADC plans to combine the antibody with a pyrrolobenz...